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Abstract
Background: The Worldwide Antimalarial Resistance Network (WWARN) is a global collaboration to support the
objective that anyone affected by malaria receives effective and safe drug treatment. The Pharmacology module
aims to inform optimal anti-malarial drug selection. There is an urgent need to define the drug exposure - effect
relationship for most anti-malarial drugs. Few anti-malarials have had their therapeutic blood concentration levels
defined. One of the main challenges in assessing safety and efficacy data in relation to drug concentrations is the
comparability of data generated from different laboratories. To explain differences in anti-malarial pharmacokinetics
in studies with different measurement laboratories it is necessary to confirm the accuracy of the assay methods.
This requires the establishment of an external quality assurance process to assure results that can be compared.
This paper describes this process.
Methods: The pharmacology module of WWARN has established a quality assurance/quality control (QA/QC)
programme consisting of two separate components:
1. A proficiency testing programme where blank human plasma spiked with certified reference material (CRM) in
different concentrations is sent out to participating bioanalytical laboratories.
2. A certified reference standard programme where accurately weighed amounts of certified anti-malarial reference
standards, metabolites, and internal standards are sent to participating bioanalytical and in vitro laboratories.
Conclusion: The proficiency testing programme is designed as a cooperative effort to help participating laboratories
assess their ability to carry out drug analysis, resolve any potential problem areas and to improve their results - and,
in so doing, to improve the quality of anti-malarial pharmacokinetic data published and shared with WWARN.
By utilizing the same source of standards for all laboratories, it is possible to minimize bias arising from poor qual-
ity reference standards. By providing anti-malarial drug standards from a central point, it is possible to lower the
cost of these standards.
Background
The Worldwide Antimalarial Resistance Network
(WWARN) is a global collaboration, established in 2009,
with the support of the Bill and Melinda Gates Founda-
tion. The aim is to support the objective that anyone
affected by malaria receives effective and safe drug treat-
ment. Working closely with WHO, WWARN has the
goal of providing urgently needed, comprehensive,
timely and quality assured information to track the
emergence and spread of anti-malarial drug resistance
so that global efforts to control the disease are founded
on reliable information. WWARN validates and provides
tools to obtain this information and shares data from a
continuously updated database. The Network supports
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endemic countries and is coordinated through regional
centres established in malaria-endemic areas.
The Asia Regional Centre is the first such coordinating
centre, operating out of Mahidol University in Bangkok,
Thailand. WWARN is composed of six complementary
modules [1] Clinical, Pharmacology, In vitro, Molecular,
Informatics and Anti-malarial Quality. Achieving ade-
quate anti-malarial drug concentrations in the blood is
essential for reliable cure of malaria. The Pharmacology
module aims to inform optimal anti-malarial drug selec-
tion and dosing by characterizing individual and popula-
tion blood concentration profiles, thereby assessing the
therapeutic ratio in different patient groups, estimating
selection pressures and differentiating resistance
from under-dosing. This review outlines the approaches
taken and methods used by the WWARN Pharmacology
module.
Pharmacology module
Therapeutic failure is not always an indication of resis-
tance to the malaria parasite. It may be the result of poor
drug quality, inadequate dosing, vomiting, poor absorp-
tion, or reduced drug exposure because of increases in
the apparent volume of distribution or clearance. More-
over, it is essential that anti-malarial drug concentration
profiles are characterized in all key target populations so
that dosage regimens can be optimized. The choice of
the optimal dose is dependent on many, often interre-
lated factors such as tablet size, acceptability, toxicity as
well as the pharmacokinetic properties of the drug(s)
used (which may vary with e.g. age, body mass, disease
severity, coadministered food, and pregnancy). There is
always a trade-off between simplicity and accuracy of the
mg/kg dose. Low dosage increases the risk of treatment
failure while high dosage may increase side effects. As
current dose recommendations were often developed for
acute uncomplicated malaria in adults, vulnerable popu-
lations (e.g. infants, malnourished children or pregnant
women) may receive inappropriate dosage of the cur-
rently recommended anti-malarials [2-5].
There is an urgent need to define the drug exposure -
effect (i.e. the pharmacokinetic-pharmacodynamic; PK-
PD) relationship for most anti-malarial drugs. Few anti-
malarials have had their therapeutic blood concentration
levels defined [6-9]. Studies on artemisinin combinations
have shown that a single time point (i.e. the day 7 con-
centration of the slowly eliminated partner drug) is a
valuable determinant of total drug exposure and conse-
quently treatment outcome [6,7,9].
One of the main challenges in assessing safety and
efficacy data in relation to drug concentrations in var-
ious patient populations is the comparability of data
generated from different laboratories. The same issues
bedevils comparison of in vitro susceptibility assess-
ments [10]. To explain differences in anti-malarial phar-
macokinetics in studies with different measurement
laboratories (or assays performed at different times) it is
necessary to confirm the accuracy of the assay methods.
This requires the establishment of an external quality
assurance process to assure results that can be com-
pared [11]. This paper describes how this process was
set up. The results from different laboratories can now
be compared through a proficiency testing programme
[12]. Inter-laboratory biases can be minimized through
the use of reliable reference standards, implementation
of quality systems, and external proficiency testing.
The pharmacology module of WWARN has estab-
lished a quality assurance/quality control (QA/QC) pro-
gramme consisting of two separate components:
1. A proficiency testing programme where blank
human plasma spiked with certified reference mate-
rial (CRM) in different concentrations is sent out to
participating bioanalytical laboratories. The quality
control samples will help laboratories in the tracking
of potential problem areas. The QA/QC unit will
also provide assistance and advice to help labora-
tories solve quality or methodological issues that
might arise during testing.
2. A certified reference standard programme where
accurately weighed amounts of certified anti-malarial
reference standards, metabolites, and internal stan-
dards are sent to participating bioanalytical and in
vitro laboratories.
Rationale
The pharmacology module of WWARN is dedicated to
provide the necessary tools to ensure that pharmacology
data generated around the globe is reliable and of a high
standard. Informing optimal anti-malarial selection and
dosing requires the global cooperation of researchers
active in anti-malarial pharmacology to define ade-
quately therapeutic drug concentrations and facilitate a
better understanding of the patient, dosing and disease
factors that change anti-malarial exposure sufficiently to
compromise the anti-malarial efficacy (or safety). From
the above it is evident that a well controlled pharmacol-
ogy QA/QC programme will not only benefit the quality
of data to be uploaded to the WWARN database, but
also patients, contributing to the control, and eventual
elimination, of malaria.
Definitions
Quality assurance (QA)
QA aims at improving and stabilizing processes to mini-
mize or avoid issues that lead to unreliable results.
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QC also known as external quality assessment (EQA) or
proficiency testing (PT) emphasizes testing and blocks
the release of unreliable results.
Reference material programme
The reference material programme is based in the Phar-
macology Department of the Mahidol-Oxford Research
Unit, Faculty of Tropical Medicine, Mahidol University,
Bangkok but operates as an independent entity. By pro-
viding anti-malarial drug standards from a central point,
the total cost of these standards can be lowered substan-
tially. Initially, laboratories may freely participate in the
QA/QC programme and receive standards and profi-
ciency testing samples without charge. In the future,
WWARN will have to introduce a cost-recovery system
to ensure the programme is sustainable, whilst main-
taining wide access to the services. Participants will be
notified of any intended changes in advance. The QA/
QC unit acquires all anti-malarial drug standards,
metabolite standards and internal standards from an
independent contract research and development organi-
zation that specializes in the synthesis of stable isotope-
labelled compounds, metabolites and pharmaceutical
related substances. All reference materials and standards
are accompanied by certificates of analysis (CoA). Re-
certification of each material is done 1 month prior to
expiry date. Reference standards are stored at the QA/
QC unit under optimal conditions and humidity, tem-
perature, and stability data are monitored continuously
to maximize usage of the materials. By utilizing the
same source of standards and same weighing procedures
for all laboratories, it is possible to minimize bias arising
from poor quality standards and weighing inaccuracies.
The QA/QC unit sends out small, accurately weighed
samples of anti-malarial reference standards, metabolites
and internal standards to research groups that are regis-
tered with the programme. Common standards and
metabolites will be supplied in 20 mg quantities while
rare metabolites and internal standards will be accu-
rately weighed in amounts of 0.4000 - 2.000 mg into
inert disposable micro weighing boats on a sensitive
ultra micro balance (Figures 1 and 2). Custom made
inert disposable micro weighing boats will be available
to the laboratories upon request.
The balance has an uncertainty at the 1 mg level of
±0.0013 mg. The balance is calibrated annually with
traceable weights by an accredited company. The cali-
bration certificate is kept on file and a copy can be
obtained upon request. As an example, if the amount of
0.4000 mg is weighed it will introduce an error of less
than ±0.33% of the final result. The overall procedure
used is based on Good Weighing Practice (GWP) princi-
ples and is described in internal standard operating
procedures. Various tests were done under different
conditions to obtain the optimum conditions prior to
commencement of weighing standards. Tests were done
for accuracy, precision and stability of the balance by
repeated weighing Class E2 weights and then calculating
averages and standard deviations over varying times. As
an example, for six series of sixty readings each (every
five seconds for five minutes) a mean weight of 1.0011 mg
(sd 0.0002) was obtained from a weight certified to have
a nominal weight of 1.0010 mg. The balance is housed in
ap l e x i g l a s sc a b i n e to nas t a b l ev i b r a t i o n - f r e ep l a t f o r m
and is always in a standby state. The room is temperature
and humidity controlled. Local power supply is compli-
mented by an uninterruptable power supply (UPS) and is
sufficiently stable. The balance is turned on and left to
stabilize for four hours before use. Three different
weights are checked and the results recorded on a log
sheet (see Figure 3). This log sheet indicates a ‘Pass’ or
‘Fail’ status for each weight using calculated uncertainty
limits for both the weights and the balance. Balance
check weights are Class E2. These weights are calibrated
Figure 1 Micro weighing boat on balance.
Figure 2 Micro weighing boat in cryovial.
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accredited company. The weight calibration check is car-
ried out before each series of weighings. A copy of the
log sheet is provided with every mailing (Figure 3). Com-
mon standards and metabolites supplied in 20 mg quan-
tities will need to be accurately weighed out by the
receiving laboratory before use. Rare metabolites and
internal standards are weighed out accurately by the QA/
QC unit and can be used (dissolved) as they arrive. The
precise weight of each rare metabolite or internal stan-
dard is recorded automatically and electronically before
the weighing boat is transferred to a 2 ml cryovial. A set
of two cryovials for each standard is sent to requesting
laboratories where an appropriate amount of solution
will be added directly to the tube to produce Reference
Stock Solutions (RSS) ranging between 0.4-2.0 mg/ml. It
is recommended that two vials (i.e. one set) are reconsti-
tuted each time an RSS needs to be prepared. The two
vials (RSS1 and RSS2) should be analysed using appropri-
ate methods at the site and the result compared. An
alternative approach is to prepare standards using RSS1
and QC samples using RSS2, analyse them and compare
the results. The deviation from the stated weight should
be <|method imprecision| + 2%. These RSS have a shelf-
life of up to 1 month when stored at 4°C. Many RSS can
also be successfully stored as aliquots at -80°C with an
increased shelf-life.
Proficiency testing (PT) programme
Day-to-day running of the PT programme is the respon-
sibility of the WWARN QA/QC unit while the long-term
strategic planning is decided together with an interna-
tional programme advisory committee comprising an
analytical pharmacologist, a clinician and a statistician.
The current members of the committee are noted on the
QA/QC programme page of the WWARN website [1].
All practices and procedures of the WWARN QA/QC
unit are documented in their own quality management
system (QMS). Selected procedures will be available
through the WWARN web site as a guide to participating
laboratories [1]. The WWARN QA/QC unit will keep
participants informed about the efficiency of the pro-
gramme as a whole, any changes that are being intro-
duced, and how any problems have been dealt with. The
Figure 3 Example of Calibration Check certificate.
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by an independent accreditation body as part of the
WWARN QA/QC units’ proficiency testing provider
accreditation. Overall direction of the programme will be
overseen by the programme advisory committee. The
unit makes use of International Harmonized Protocol for
the Proficiency Testing of (Chemical) Analytical Labora-
tories as published in an IUPAC technical report [13].
Participation in the PT programme is open to all
laboratories. The QA/QC unit will provide registration
documents upon request. The principal investigator of a
laboratory must complete the registration form and
return it to the QA/QC unit who will then evaluate the
application. The proficiency testing programme is lim-
ited to laboratories doing either clinical studies or
research on anti-malarial drugs. In the first six months
of operation, eight analytical laboratories registered with
the WWARN PT programme.
PT samples will be distributed to the participants once
per year. All samples will be sent in a single shipment
but testing will be assessed in three cycles per year. The
first cycle starts in January and ends by 30
th April, the
second cycle starts in May and ends by 31
st August and
the last and third cycle starts in September and ends by
31
st December. Samples may be requested from the
WWARN QA/QC unit at any time within a cycle. How-
ever, results must be reported within two weeks after
the end of the cycle. The assigned value (i.e. concentra-
tion) for each anti-malarial drug substance in each sam-
ple will be disclosed to participants together with
anonymized results from all participating laboratories
after each cycle. Participants should use their preferred
analytical method i.e. those used by the participating
laboratory for routine analysis and not versions of the
method specially adapted for the proficiency test. Each
laboratory will be given a unique code, and will only be
able to identify their laboratory in the result reports.
The results will be subjected to statistical analysis and
converted into scores by the WWARN QA/QC unit. All
participants will be kept fully informed of the progress
of the programme at all times.
The WWARN QA/QC unit will prepare all PT sam-
ples in-house using certified reference material and
characterized healthy volunteer sodium heparin plasma.
Other matrixes will be added in the future. PT samples
are spiked with anti-malarial drugs and drug metabolites
according to valid internal SOPs. Samples are frozen at
-80°C immediately after preparation. The proficiency
testing programme makes use of an international cour-
ier service with experience in shipping biological mate-
rial. No materials will be shipped without the required
documents in place. The PT programme will initially
include PT samples for dihydroartemisinin, chloroquine
and lumefantrine but other drugs will be included as the
programme progresses after discussions with the advi-
sory committee.
Participating laboratories should report results in a
spreadsheet format indicating the units of measurement.
Results below the lower limit of quantification (LLOQ) for
a specific method in a laboratory should not be reported
but the LLOQ for each analyte (drug/metabolite) must be
reported so that the standard deviation for proficiency
assessment (SDPA) can be calculated on an individual
basis for each PT sample. Results submitted after the
deadline for that cycle will be rejected, and submitted
results cannot be corrected or withdrawn. The reason for
this stringent approach is that proficiency testing is
intended to test every aspect of the analytical process,
including calculating, checking, and reporting a result.
Assessment of performance
For each drug in a cycle, a criterion of performance is
determined against which the performance level
obtained by a laboratory can be assessed. The perfor-
mance criterion is set so as to ensure that the analytical
data routinely produced by the laboratory is of a quality
that is adequate for its intended purpose. The WWARN
QA/QC unit continuously evaluates different approaches
for assessment of performance. The goal is to select the
approach which best evaluates whether the methods are
fit for purpose (i.e. to quantify sample concentrations in
line with international guidelines). The standard assess-
ment below will always be carried out. The WWARN
QA/QC unit will notify all participating laboratories of
any change in the assessment of performance prior to
each cycle. Laboratories are assessed on the difference
between their result and the assigned value for each PT
sample. A performance score for each PT sample will be
calculated for each laboratory using the following formula:
zx x =− () S D P A a /
where z is the performance score
x is the participant result
xa is the assigned value
SDPA is the standard deviation for proficiency
assessment
Assigned value (xa)
The assigned value xa is determined by one of the fol-
lowing methods:
1. formulation (i.e., the nominal value assigned on
the basis of proportions of drug reference material
used in spiked PT samples)
2. a consensus value (i.e., an average value derived
directly from the reported results of all participating
laboratories)
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WWARN QA/QC programme determines what method
will be used to determine the assigned value. The QA/
QC unit will compare the average value of all participat-
ing laboratories with the formulation value after each
cycle. If large unexplained discrepancies are found, the
QA/QC unit will initiate an investigation for the root
cause.
Standard deviation for proficiency assessment (SDPA)
The revised Harmonized Protocol (HP) describes several
ways in which the SDPA can be obtained. It can, for
example, be determined in a proficiency test as the stan-
dard deviation of all the laboratory results (excluding
significant outliers). However the HP recommends that
the SDPA is a set value, which corresponds to the preci-
sion needed to perform a certain task. The HP calls this
SDPA the “fitness-for-purpose b a s e ds t a n d a r dd e v i a t i o n
for proficiency assessment [14].
The WWARN QA/QC unit will calculate the SDPA
for each PT sample based on the LLOQ reported by the
laboratory. This means that the same PT sample could
produce different SDPA for different laboratories
depending on the LLOQ for their respective method.
See example below (Table 1).
Calculation of SDPA for each PT sample [15].
1 - 3× LLOQ ±25% of the assigned value
>3 - 10× LLOQ ±20% of the assigned value
>10× LLOQ ±15% of the assigned value
The z-score
The z-score is an indication of the proficiency of a
laboratory and will be graded to the following schedule
for each individual PT sample [16]:
1. |z| < 2: the result is considered satisfactory.
2. 2 < |z| < 3: the result is considered questionable.
3. |z| > 3: the result is considered unsatisfactory.
The WWARN QA/QC unit will provide a perfor-
mance report to each participant for each cycle where
the overall performance will be appraised as follows
[17]:
1. Satisfactory performance is the successful analysis
o fad r u gb yt h el a b o r a t o r y( M o r et h a n8 0 %o fa l l
z-scores for a drug < 2). No further action is necessary
and the laboratory demonstrated proficiency in carrying
out analysis for that particular drug.
2. Questionable performance is when the laboratory
produces more than 20% of all z-scores for a drug > 2
but less than 10% > 3. The laboratory is advised to com-
pletely investigate every aspect of the questionable and
unsatisfactory results (|z| > 2) to prevent recurrence of
this problem or any other problem identified during the
investigation.
3. Unsatisfactory performance is when the laboratory
produces more than 20% of all z-scores for a drug > 3.
The laboratory is advised to completely investigate every
aspect of the unsatisfactory results to prevent recurrence
of this problem or any other problem identified during
the investigation.
4. Unsuccessful performance is when the laboratory
displays unsatisfactory performance for a drug for two
consecutive or two out of three cycles. The laboratory is
advised to completely investigate every aspect of the
analytical methodology and re-confirm method valida-
tion performance.
5. Critical performance is when the laboratory dis-
plays unsatisfactory performance f o rad r u gf o rt h r e e
consecutive cycles. The laboratory is advised to cease
testing until all necessary actions are taken to correct
performance
Laboratories that do not meet the criteria for success-
ful performance for a given drug are encouraged to
contact the WWARN QA/QC unit. The QA/QC unit
will provide assistance and advice to help laboratories
solve quality or methodological issues that might arise
during testing. Reports issued to participants will be
clear and comprehensive and show the distribution of
anonymized results from all laboratories together with
the participant’s performance score. Test results used by
the WWARN QA/QC unit in all calculations will be
provided, to enable participants to check that their data
have been correctly entered. Reports will be made avail-
able as quickly as possible after the return of results to
the WWARN QA/QC unit. Participants will receive
reports in clear and simple format with summary results
in graphical form (e.g., as a histogram, bar chart, or
other distribution plot) with appropriate summary
statistics.
Summary statistics of the programme will be posted
by means of anonymous identifiers via the WWARN
website. Participants will be identified in reports by code
only. Participants in the proficiency testing programme
Table 1 Example of SDPA for different LLOQ’s
QC Sample QC1 QC2 QC3 QC4
Assigned value 5 20 100 500
SDPA (%) SDPA (value) SDPA (%) SDPA (value) SDPA (%) SDPA (value) SDPA (%) SDPA (value)
Lab 1 LLOQ 1 20% 1 15% 3 15% 15 15% 75
Lab 2 LLOQ 20 <LLOQ 25% 5 20% 20 15% 75
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lar programme reports, privately to a laboratory accredi-
tation or other assessment body when required for the
purpose of assessment, or to clients for the purpose of
demonstrating analytical capability.
On joining the programme, participants are provided
with detailed information, including:
￿ the range of tests available and the tests the partici-
pant has elected to undertake;
￿ the method of setting performance criteria;
￿ performance criteria applicable at the time of join-
ing, unless criteria are set separately for each test
material;
￿ the method(s) of determining assigned values,
including measurement methods where relevant;
￿ a summary of the statistical procedures used to
obtain participant scores;
￿ information on interpreting scores;
￿ conditions pertaining to participation (e.g., avoidance
of collusion with other participants);
￿ the composition and method of selection of the
advisory committee; and
￿ contact details for the WWARN QA/QC unit and
any other relevant organizations.
Participants will be advised of any forthcoming
changes in programme design or operation, and will be
encouraged to provide feedback on all aspects of pro-
gramme operation and on problems with individual test
materials. In this way, participants will contribute to the
development of the programme and to alerting the
WWARN QA/QC unit to any unanticipated difficulty
with its system and PT samples.
Conclusion
The WWARN QA/QC programme is a dynamic pro-
gramme for the distribution of certified reference stan-
dards and proficiency testing samples for anti-malarial
drug measurement. It will facilitate clinical pharmacoki-
netic and in vitro sensitivity studies around the world.
The proficiency testing programme is designed as a
cooperative effort to help participating laboratories
assess their ability to carry out drug analysis, resolve any
potential problem areas and to improve their results -
and, in so doing, to improve the quality of anti-malarial
pharmacokinetic data published and shared with
WWARN. To ensure the quality of pharmacokinetic
data, it is important that laboratories use validated and
accurate methods, but equally important that results are
compared with other laboratories. By utilizing the same
source of standards for all laboratories, it is possible to
minimize bias arising from poor quality reference stan-
dards. By providing anti-malarial drug standards from a
central point, it is possible to lower the cost of these
standards. This process both assesses and empowers.
Laboratories which can provide evidence of the accuracy
of their analytical methods can prove to their host insti-
tutions, sponsors, and professional colleagues that they
are performing at a high standard. This innovative
approach improves trust, and could help translate evi-
dence into policy and practice. It is hoped that similar
programmes can be developed for other anti-infective
drug measurement in tropical countries. The WWARN
QA/QC unit will review the outcomes of every cycle of
the programme, noting, for example, any strengths,
weaknesses, specific problems, and opportunities for
improvement. Every aspect of the operation of the pro-
gramme, including any issues identified by the partici-
pants is continuously monitored and feedback from
participants is encouraged.
This programme will hopefully facilitate for groups to
conduct and analyse clinical pharmacokinetic studies of
the highest quality and thereby generate desperately
needed data on anti-malarial pharmacology and its
impact on treatment response. The WWARN QA/QC
programme is dedicated to provide a service of the high-
est standard and to this effect is pursuing proficiency
testing provider accreditation from a nationally recog-
nized accreditation body. It is envisaged that accredita-
tion will be obtained as soon as the first cycle of the
quality control programme is completed. Participating
laboratories will then also be able to use their perfor-
mance in the WWARN QA/QC programme as addi-
tional proof of their standard of service [18]. They may
also quote their results in scientific publications. Con-
tact information for the WWARN QA/QC unit can be
found through the WWARN website where also regis-
tration forms for the proficiency testing programme
and/or the reference material programme can be
requested [1].
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